Modified PEST Screening for Psoriatic Arthritis
(ScreenX Trial)
Recruiting at1 trial location
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: Novartis Pharmaceuticals
No Placebo Group
Trial Summary
What is the purpose of this trial?
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
Research Team
NP
Novartis Pharmaceuticals
Principal Investigator
Novartis Pharmaceuticals
Eligibility Criteria
This trial is for adults in Canada with moderate-to-severe plaque psoriasis who might need biologic DMARDs (a type of medication). Participants should understand and be willing to follow the study's rules.Inclusion Criteria
Key
I live in Canada.
I have severe plaque psoriasis and qualify for biological treatments.
See 2 more
Treatment Details
Interventions
- PEST Screening group (Behavioural Intervention)
Trial OverviewThe study is testing a modified PEST screening tool, which includes additional questions and pictures, to see if it helps diagnose Psoriatic Arthritis in people with severe plaque psoriasis more effectively.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: PEST Screening groupExperimental Treatment1 Intervention
When visiting their dermatologists, all eligible patients with moderate-to-severe plaque psoriasis (PsO) eligible for treatment with biologic Disease-Modifying Antirheumatic Drugs (bDMARDs) will be screened for psoriatic arthritis (PsA) using PEST+pictures+2, a variation of the PEST screening tool.
The PEST+pictures+2 is made up of 3 components:
1. Psoriasis Epidemiology Screening Tool (PEST) consisting of 5 simple questions
2. PEST+2 refers to the PEST modified with two additional questions (Do you have morning stiffness that lasts for more than one (1) hour? Do you wake up at night because of low back or buttock pain?), AND
3. PEST+pictures which provides an opportunity for patients to modify their answers to PEST questions 1, 3, and 5 by presenting them with pictures of swollen joints, fingernail pitting, and swollen fingers and toes.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Trials
2,963
Recruited
4,275,000+
Founded
1996
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Gleevec, Cosentyx, Entresto, Kisqali
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD